These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10683025)

  • 1. Management of unstable coronary-artery disease.
    Cohen AT
    Lancet; 2000 Feb; 355(9203):574. PubMed ID: 10683025
    [No Abstract]   [Full Text] [Related]  

  • 2. Low molecular weight heparins in acute coronary syndrome.
    Creekmore F
    S D J Med; 2000 Jan; 53(1):21-3. PubMed ID: 10652862
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low molecular weight heparin: a bridge over troubled water.
    Verheugt FW
    Eur Heart J; 2002 Aug; 23(15):1144-6. PubMed ID: 12127917
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
    Wallentin L; Husted S; Kontny F; Swahn E
    Am J Cardiol; 1997 Sep; 80(5A):61E-63E. PubMed ID: 9296473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes. A panel discussion with audience participation.
    Chesebro JH; Verheugt FW; Kontny F; Fry ET; Wallentin L; Camm AJ; Bechtold H
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I20-2. PubMed ID: 11286311
    [No Abstract]   [Full Text] [Related]  

  • 9. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin in the treatment of unstable angina. Can the decrease of the molecular size increase its effectiveness?].
    Panchenko EP
    Ter Arkh; 1998; 70(12):71-4. PubMed ID: 10067259
    [No Abstract]   [Full Text] [Related]  

  • 12. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
    Topol EJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950
    [No Abstract]   [Full Text] [Related]  

  • 13. Acute coronary care and beyond: the expanding role of low-molecular-weight heparin.
    Verheugt FW; Chesebro JH
    Clin Cardiol; 2001 Mar; 24(3 Suppl):I1-2. PubMed ID: 11286308
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-molecular weight heparins.
    Talley JD
    J Ark Med Soc; 1997 Apr; 93(11):555-6. PubMed ID: 9114648
    [No Abstract]   [Full Text] [Related]  

  • 15. Dalteparin for acute coronary syndromes.
    O'Loughlin DC
    Heart Dis; 1999; 1(5):329-36. PubMed ID: 11720639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute management--how should we intervene?
    Kontny F
    Clin Cardiol; 2000 Jan; 23 Suppl 1(Suppl):I8-12. PubMed ID: 10680038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Low molecular weight heparin in unstable angina].
    Kher A; Samama MM
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1495-500. PubMed ID: 9092409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New trials of LMW heparins - light and heavy weight as good on short but what about longer distances?
    Wallentin L
    Eur Heart J; 1999 Nov; 20(21):1522-4. PubMed ID: 10529316
    [No Abstract]   [Full Text] [Related]  

  • 20. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.